| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CMAX | Class A Common Stock | Options Exercise | +12.1K | 12.1K | Nov 17, 2023 | Through Deerfield Management Company, L.P. | F1, F2, F3, F4 | |||
| holding | CMAX | Class A Common Stock | 15.8M | Nov 17, 2023 | Through Deerfield Partners, L.P. | F3, F4 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CMAX | Restricted Stock Units | Options Exercise | $0 | -12.1K | -100% | $0.00* | 0 | Nov 17, 2023 | Class A Common Stock | 12.1K | Through Deerfield Management Company, L.P. | F2, F3, F4, F5 |
| Id | Content |
|---|---|
| F1 | The reported transaction involved the vesting and settlement of 12,123 restricted stock units ("RSUs") on November 17, 2023. On such date, each such RSU vested in full and converted into Class A common stock of the Issuer on a one-for-one basis. |
| F2 | Kevin Berg, an employee of Deerfield Management Company, L.P. ("Deerfield Management"), serves as a director of the Issuer. The RSUs granted to Mr. Berg were held for the benefit, and at the direction, of Deerfield Management. |
| F3 | This Form 4 is being filed by the undersigned as well as the entity listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). James E. Flynn is the sole member of the general partner of Deerfield Management and of the general partner of Deerfield Partners, L.P. Deerfield Management is the investment manager of Deerfield Partners, L.P. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. |
| F4 | In accordance with Instruction 4(b)(iv) to Form 4, the entire amount of the Issuer's securities held by Deerfield Management and Deerfield Partners is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. |
| F5 | Each RSU was awarded on November 17, 2022, vested on November 17, 2023 and represented a contingent right to receive one share of the Issuer's Class A common stock in accordance with the Issuer's 2021 Long-Term Incentive Plan. |
Kevin Berg, an employee of Deerfield Management, serves as a director of the Issuer. Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 4 with regard to DA32 Life Science Tech Acquisition Corp. filed with the Securities and Exchange Commission on August 3, 2021 by Deerfield Partners, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and James E. Flynn.